JP2006507225A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006507225A5 JP2006507225A5 JP2004515703A JP2004515703A JP2006507225A5 JP 2006507225 A5 JP2006507225 A5 JP 2006507225A5 JP 2004515703 A JP2004515703 A JP 2004515703A JP 2004515703 A JP2004515703 A JP 2004515703A JP 2006507225 A5 JP2006507225 A5 JP 2006507225A5
- Authority
- JP
- Japan
- Prior art keywords
- antagonist
- glutamate receptor
- metabotropic glutamate
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 claims 12
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 claims 12
- 239000005557 antagonist Substances 0.000 claims 12
- 230000003287 optical effect Effects 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 8
- 230000002265 prevention Effects 0.000 claims 5
- 208000006673 asthma Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 2
- 210000000111 lower esophageal sphincter Anatomy 0.000 claims 2
- 239000003512 metabotropic receptor antagonist Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 238000010992 reflux Methods 0.000 claims 2
- 230000001052 transient effect Effects 0.000 claims 2
- NEWKHUASLBMWRE-UHFFFAOYSA-N 2-methyl-6-(phenylethynyl)pyridine Chemical group CC1=CC=CC(C#CC=2C=CC=CC=2)=N1 NEWKHUASLBMWRE-UHFFFAOYSA-N 0.000 claims 1
- PKDHDJBNEKXCBI-UHFFFAOYSA-N 2-methyl-6-(phenylethynyl)pyridine hydrochloride Chemical group Cl.CC1=CC=CC(C#CC=2C=CC=CC=2)=N1 PKDHDJBNEKXCBI-UHFFFAOYSA-N 0.000 claims 1
- NBFUGBSVJORKJO-UHFFFAOYSA-N 3-[3-(5-fluoropyridin-2-yl)-1,2,4-oxadiazol-5-yl]-5-(methoxymethyl)benzonitrile Chemical group COCC1=CC(C#N)=CC(C=2ON=C(N=2)C=2N=CC(F)=CC=2)=C1 NBFUGBSVJORKJO-UHFFFAOYSA-N 0.000 claims 1
- RBSPCALDSNXWEP-UHFFFAOYSA-N 3-fluoro-5-[3-(5-fluoropyridin-2-yl)-1,2,4-oxadiazol-5-yl]benzonitrile Chemical group N1=CC(F)=CC=C1C1=NOC(C=2C=C(C=C(F)C=2)C#N)=N1 RBSPCALDSNXWEP-UHFFFAOYSA-N 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 201000007100 Pharyngitis Diseases 0.000 claims 1
- 206010067171 Regurgitation Diseases 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 208000037824 growth disorder Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0201943A SE0201943D0 (sv) | 2002-06-20 | 2002-06-20 | New use |
| PCT/US2003/016223 WO2004000316A1 (en) | 2002-06-20 | 2003-06-19 | Use of mglur5 antagonists for the treatment of gerd |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010268162A Division JP2011068669A (ja) | 2002-06-20 | 2010-12-01 | Ｇｅｒｄの治療のためのｍｇｌｕｒ５アンタゴニストの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006507225A JP2006507225A (ja) | 2006-03-02 |
| JP2006507225A5 true JP2006507225A5 (enExample) | 2006-07-20 |
| JP4683920B2 JP4683920B2 (ja) | 2011-05-18 |
Family
ID=20288301
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004515703A Expired - Fee Related JP4683920B2 (ja) | 2002-06-20 | 2003-06-19 | Ｇｅｒｄの治療のためのｍｇｌｕｒ５アンタゴニストの使用 |
| JP2010268162A Pending JP2011068669A (ja) | 2002-06-20 | 2010-12-01 | Ｇｅｒｄの治療のためのｍｇｌｕｒ５アンタゴニストの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010268162A Pending JP2011068669A (ja) | 2002-06-20 | 2010-12-01 | Ｇｅｒｄの治療のためのｍｇｌｕｒ５アンタゴニストの使用 |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP1513525B1 (enExample) |
| JP (2) | JP4683920B2 (enExample) |
| CN (1) | CN100430056C (enExample) |
| AT (1) | ATE395059T1 (enExample) |
| AU (1) | AU2003241585B2 (enExample) |
| BR (1) | BR0311759A (enExample) |
| CA (1) | CA2489730C (enExample) |
| CY (1) | CY1107954T1 (enExample) |
| DE (1) | DE60320990D1 (enExample) |
| DK (1) | DK1513525T3 (enExample) |
| ES (1) | ES2304510T3 (enExample) |
| IL (1) | IL165138A0 (enExample) |
| IS (1) | IS7654A (enExample) |
| MX (1) | MXPA04012659A (enExample) |
| NO (1) | NO20050154L (enExample) |
| NZ (1) | NZ536559A (enExample) |
| PL (1) | PL372186A1 (enExample) |
| PT (1) | PT1513525E (enExample) |
| RU (1) | RU2324484C2 (enExample) |
| SE (1) | SE0201943D0 (enExample) |
| SI (1) | SI1513525T1 (enExample) |
| UA (1) | UA81627C2 (enExample) |
| WO (1) | WO2004000316A1 (enExample) |
| ZA (1) | ZA200409908B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7964609B2 (en) | 2002-06-20 | 2011-06-21 | Astrazeneca Ab | Use of mGluR5 antagonists for the treatment of gerd |
| SE0303418D0 (sv) * | 2003-12-17 | 2003-12-17 | Astrazeneca Ab | New use 1 |
| WO2005060971A1 (en) * | 2003-12-18 | 2005-07-07 | Astrazeneca Ab | Treatment of reflux-related diseases |
| WO2005060961A2 (en) * | 2003-12-18 | 2005-07-07 | Astrazeneca Ab | Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd) |
| WO2005077345A1 (en) * | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Compounds for the treatment of gastro-esophageal reflux disease |
| WO2005077368A2 (en) * | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| CN1934097A (zh) * | 2004-02-18 | 2007-03-21 | 阿斯利康(瑞典)有限公司 | 炔基化哌嗪化合物及其作为代谢型谷氨酸受体拮抗剂的应用 |
| TW200538179A (en) * | 2004-02-18 | 2005-12-01 | Astrazeneca Ab | Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists |
| GB0514296D0 (en) * | 2005-07-12 | 2005-08-17 | Novartis Ag | Organic compounds |
| RU2451673C2 (ru) * | 2006-03-29 | 2012-05-27 | Ф. Хоффманн-Ля Рош Аг | ПРОИЗВОДНЫЕ ПИРИДИНА И ПИРИМИДИНА В КАЧЕСТВЕ АНТАГОНИСТОВ mGluR2 |
| JP2010502664A (ja) | 2006-09-11 | 2010-01-28 | ノバルティス アクチエンゲゼルシャフト | 代謝型グルタミン酸受容体の調節剤としてのニコチン酸誘導体 |
| JP2008245225A (ja) * | 2007-03-29 | 2008-10-09 | Kddi Corp | 波長パス経路決定装置、波長パス設定制御システム及びプログラム |
| WO2009024491A1 (en) * | 2007-08-20 | 2009-02-26 | F. Hoffmann-La Roche Ag | Use of mglur5 antagonists for the treatment of gerd |
| US8703809B2 (en) | 2008-06-30 | 2014-04-22 | Novartis Ag | Combination products |
| US20120157464A1 (en) | 2009-07-23 | 2012-06-21 | Novartis Ag | Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives for the treatment or prevention of ataxia |
| JO3250B1 (ar) | 2009-09-22 | 2018-09-16 | Novartis Ag | إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7 |
| EP2490691A1 (en) | 2009-10-20 | 2012-08-29 | Novartis AG | Use of 1h-quinazoline-2,4-diones |
| US20130096145A1 (en) | 2010-06-24 | 2013-04-18 | Novartis Ag | Use of 1H-quinazoline-2,4-diones |
| JP2014503568A (ja) | 2011-01-27 | 2014-02-13 | ノバルティス アーゲー | ニコチン酸アセチルコリン受容体α７活性化因子の使用 |
| BR112014005210A2 (pt) | 2011-09-07 | 2017-03-21 | Novartis Ag | uso de 1h-quinazolina-2,4-dionas para uso na prevenção ou tratamento da epilepsia fotossensível |
| CA2898045C (en) | 2013-01-15 | 2018-08-28 | Novartis Ag | Use of alpha 7 nicotinic acetylcholine receptor agonists |
| JP6137336B2 (ja) | 2013-01-15 | 2017-05-31 | ノバルティス アーゲー | ナルコレプシーの処置のためのアルファ７ニコチン性受容体アゴニストの使用 |
| ES2961678T3 (es) * | 2019-11-05 | 2024-03-13 | Claes Thulin | 4-[5-[(rac)-1-[5-(3-clorofenil)-3-isoxazolil]etoxi]-4-metil-4h-1,2,4-triazol-3-il]piridina para su uso en la prevención y/o el tratamiento del estrés |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU594424B2 (en) * | 1986-01-03 | 1990-03-08 | University Of Melbourne, The | Gastro-oesophageal reflux composition |
| SE9603408D0 (sv) * | 1996-09-18 | 1996-09-18 | Astra Ab | Medical use |
| WO1999059612A1 (en) * | 1998-05-15 | 1999-11-25 | Aphton Corporation | Method for the treatment of gastroesophageal reflux disease |
| RU2144331C1 (ru) * | 1998-11-05 | 2000-01-20 | Московский НИИ уха, горла и носа | Способ лечения хронического гиперпластического ларингита |
| CA2381975A1 (en) * | 1999-08-19 | 2001-02-22 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| CA2421782A1 (en) * | 2000-10-02 | 2002-04-11 | Janssen Pharmaceutica N.V. | Quinoline and quinolinone derivatives as metabotropic glutamate receptor antagonists |
-
2002
- 2002-06-20 SE SE0201943A patent/SE0201943D0/xx unknown
-
2003
- 2003-06-19 RU RU2005101411/15A patent/RU2324484C2/ru not_active IP Right Cessation
- 2003-06-19 AU AU2003241585A patent/AU2003241585B2/en not_active Ceased
- 2003-06-19 EP EP03731333A patent/EP1513525B1/en not_active Expired - Lifetime
- 2003-06-19 SI SI200331220T patent/SI1513525T1/sl unknown
- 2003-06-19 UA UA20041210177A patent/UA81627C2/ru unknown
- 2003-06-19 DE DE60320990T patent/DE60320990D1/de not_active Expired - Lifetime
- 2003-06-19 PL PL03372186A patent/PL372186A1/xx not_active Application Discontinuation
- 2003-06-19 DK DK03731333T patent/DK1513525T3/da active
- 2003-06-19 WO PCT/US2003/016223 patent/WO2004000316A1/en not_active Ceased
- 2003-06-19 NZ NZ536559A patent/NZ536559A/en not_active IP Right Cessation
- 2003-06-19 AT AT03731333T patent/ATE395059T1/de active
- 2003-06-19 CN CNB038141760A patent/CN100430056C/zh not_active Expired - Fee Related
- 2003-06-19 PT PT03731333T patent/PT1513525E/pt unknown
- 2003-06-19 BR BR0311759-6A patent/BR0311759A/pt not_active IP Right Cessation
- 2003-06-19 MX MXPA04012659A patent/MXPA04012659A/es not_active Application Discontinuation
- 2003-06-19 CA CA2489730A patent/CA2489730C/en not_active Expired - Fee Related
- 2003-06-19 JP JP2004515703A patent/JP4683920B2/ja not_active Expired - Fee Related
- 2003-06-19 ES ES03731333T patent/ES2304510T3/es not_active Expired - Lifetime
-
2004
- 2004-11-10 IL IL16513804A patent/IL165138A0/xx unknown
- 2004-12-07 ZA ZA200409908A patent/ZA200409908B/en unknown
-
2005
- 2005-01-11 NO NO20050154A patent/NO20050154L/no not_active Application Discontinuation
- 2005-01-19 IS IS7654A patent/IS7654A/is unknown
-
2008
- 2008-05-21 CY CY20081100527T patent/CY1107954T1/el unknown
-
2010
- 2010-12-01 JP JP2010268162A patent/JP2011068669A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006507225A5 (enExample) | ||
| CA2489730A1 (en) | Use of mglur5 antagonists for the treatment of gerd | |
| JP2017528507A5 (enExample) | ||
| US20020019421A1 (en) | Compositions and therapy for substance addiction | |
| CN103458690B (zh) | 治疗肺动脉高压的组合物和方法 | |
| JP5796959B2 (ja) | 関節炎における痛みの治療のためのタペンタドール | |
| CN103402514B (zh) | 用于治疗运动障碍的血清素受体激动剂组合物 | |
| JP2009542702A5 (enExample) | ||
| WO2006059108A3 (en) | ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES | |
| JP2009542699A5 (enExample) | ||
| JP2005502643A5 (enExample) | ||
| JP2010512414A5 (enExample) | ||
| EP2942082A3 (en) | A2A receptor antogonists for use in the treatment of movement disorders | |
| JP2009533356A5 (enExample) | ||
| JP2019525948A5 (enExample) | ||
| JP2009215293A5 (enExample) | ||
| JP2019512495A5 (enExample) | ||
| JP2009532438A5 (enExample) | ||
| JP2011500673A5 (enExample) | ||
| TW200815008A (en) | Method for enhancing cognitive function | |
| US20060293309A1 (en) | Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors | |
| JP2006524203A5 (enExample) | ||
| JP2012518019A5 (enExample) | ||
| Pelaia et al. | Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD | |
| CN113453683A (zh) | 运动障碍的治疗 |